INTERLEUKIN 32 AS ANEW BIOMARKER FOR NON ALCOHOLIC FATTY LIVER DISEASE

Abstract

NAFLD is a multisystem disease, affecting extra-hepatic organs and regulatory pathways. For example, NAFLD increases risk of type 2 diabetes mellitus (T2DM), cardiovascular (CVD) and cardiac diseases, and chronic kidney disease (CKD). Although the primary liver pathology in NAFLD affects hepatic structure and function to cause morbidity and mortality from cirrhosis, liver failure and hepatocellular carcinoma, the majority of deaths among NAFLD patients are attributable to CVD. This narrative review focuses on the rapidly expanding body of clinical evidence that supports the concept of NAFLD as a multisystem disease (Byrne & Targher., 2015). IL32 is a proinflammatory cytokine known to play a role in host defense, inflammatory diseases, and cancer (reviewed in Joosten et al), as a novel factor clearly associated with NAFLD and insulin resistance in patients with obesity who underwent bariatric surgery. IL32 expression was significantly increased in the liver of patients with NAFLD, and this elevation was more pronounced in patients with NASH (Joosten et al., 2013). IL32 has a critical role in the pathogenesis of NAFLD and could be considered as a therapeutic target in patients (Dali et al., 2019).